Your source for the latest medtech news from AdvaMed® and our members.
Lima, Peru – AdvaMed®, the Medtech Association, issued the following press release following conclusion of the 2024 Asia-Pacific Economic Cooperation (APEC) Business Ethics for Small- and Medium-Sized Enterprises (SMEs) Forum in…
WASHINGTON – AdvaMed®, the Medtech Association, today praised The Centers for Medicare and Medicaid Services (CMS) Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgical Center Payment System rule for…
AdvaMed®, the Medtech Association, announced today that it has received accreditation from the premier American National Standards Institute (ANSI) to develop industry standards for medical device innovation. As an ANSI-accredited…
MedTechVets, a leading non-profit organization dedicated to supporting military veterans in transitioning into careers in the medical technology sector, proudly announces the appointment of Scott Whitaker to our Board of Directors effective…
If you have media inquiries, please contact:
Jim Jeffries, Senior Vice President, Public Affairs, 206-225-5226
MedTechVets, a leading non-profit organization dedicated to supporting military veterans in transitioning into careers in the medical technology sector, proudly announces the appointment of Ramzi Nuwayhid as Board Director effective…
Healionics Corporation, a developer of synthetic biomaterial-based medical devices, today announced 12-month clinical results in the ongoing human trial of its STARgraft arteriovenous (AV) graft (NCT05729620). STARgraft is a new…
AdvaMed®, the Medtech Association, released the following statement from President and CEO Scott Whitaker on the final Transitional Coverage for Emerging Technologies (TCET) notice from the Centers for Medicare and…
In the first episode of the new Medtech POV series “From AI to Z”, AdvaMed® President and CEO Scott Whitaker sat down with Troy Tazbaz, Director of the Digital Health…
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Shield™ blood test for colorectal cancer (CRC)…